According to research report the global contrast media market is expected to reach USD 5.53 billion by 2022 from an estimated USD 4.57 billion in 2017, growing at a CAGR of 3.9% during the forecast period. Growth in the contrast media market can primarily be attributed to factors such as increasing number of approvals for contrast agents and growing number of public & private diagnostic centres. The increasing number of research and funding activities for research of contrast agents and their applications provides immense opportunities for players in the contrast media market.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=911
Market developments (regulatory and product approvals); agreements, collaborations, contracts, and partnerships; expansions; mergers and acquisitions; and other strategies (divestments, grants, and website launches) were some of the strategies adopted by players from 2014 and 2017. The key players that adopted these strategies include GE Healthcare (US), Bracco Imaging (Italy), Bayer HealthCare (Germany), and Guerbet (France).
GE Healthcare held the first position in the global contrast media market in 2017. The firm has a strong customer base in approximately 175 countries, primarily operating in North America, Europe, the Pacific Basin, the Americas, and the Middle East & Africa. Some subsidiaries of the firm include GE Healthcare USA Holdings, Inc., GE Healthcare Ltd. (Japan), GE Healthcare Biosciences AB (US), and GE Healthcare AS (Norway). GE Healthcare received the Norwegian Medicines Agency's (NOMA) approval for SONAZOID, a contrast agent used in ultrasound imaging of focal liver lesions. However, with competition in the market and the entry of new companies, it is necessary for GE to innovate continuously in order to keep its technology at the forefront and maintain its position in the market. The company’s robust product portfolio, large number of subsidiaries, focus on customers, and new product launches have also helped expand its share in the market.
Bracco Imaging was the second largest player in the contrast media market in 2017. The company continuously strives to strengthen its market position in various geographies by focusing on receiving approvals for its contrast media products. The company also focuses on R&D and has six R&D centres present globally, in line with this Bracco invested around USD 110 million in R&D in 2015. This investment enabled the company to register more than 1,800 patents in multiple disciplines.
Bayer HealthCare was the third largest player in the contrast media market in 2017. The company provides contrast media products through its radiology business unit under the Pharmaceuticals segment. The company has a strong focus on R&D in its Pharmaceutical segment. In accordance to this, the company invested approximately 15.6%, 16.0%, and 17.0% of its Pharmaceuticals division’s revenue for R&D activities in 2014, 2015, and 2016 respectively. The company has gained a major share in the contrast media market on account of its comprehensive product portfolio, wide geographical reach, focus on organic growth strategies, and constant focus on research and developmental activities.
Get Report Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=911
Some of the other players competing in this market are Lantheus (US), Daiichi Sankyo (Japan), Unijules Life Sciences (India), J.B. Chemicals and Pharmaceuticals (India), Spago Nanomedicine (Sweden), Taejoon Pharm (South Korea), Jodas (India), and Magnus Health (India).
Contact:
Mr. Shelly Singh
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: 1-888-600-6441
It includes the size, share, growth, trends, key players, segments and regional analysis in detail during the study year 2020-2027The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide.
The major players in the ct contrast media market include GE Healthcare, Bayer, Bracco Imaging, Guerbet Group, Hengrui Medicine, Lantheus, YRPG, BeiLu Pharma, Sanochemia, Tyco Healthcare, and Imax.
This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.Get more information on "Global CT Contrast Media Market Research Report" by requesting FREE Sample Copy at https://www.valuemarketresearch.com/contact/ct-contrast-media-market/download-sampleMarket DynamicsA computed tomography (CT) scan is a broadly recognized medical imaging technique worldwide to get detailed internal body structure images for diagnostic purposes.
CT scan offers several advantages over other imaging techniques.
The key factors estimated to steer the growth of the CT contrast media market are the growing need for effective and early diagnosis, the rising global prevalence of targeted diseases, increasing preference for minimally invasive diagnostic procedures, an aging population, and benefits of CT scans over other imaging modalities.
However, the choice for other imaging diagnostic techniques over CT, such as magnetic resonance imaging (MRI) and X-radiation (x-ray), limits the demand for CT contrast media.The report covers Porter’s Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis.
